All In Biotech

Drug Trial Radar · NCT01694771

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]

Last checked: Nov 19, 2026Latest source record: Sep 4, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,134 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,134

Actual

Start

Sep 2012

Primary completion

Aug 2013

Study completion Aug 2013

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Sep 27, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall objective of this study is to assess efficacy and safety of 12 weeks, once daily, orally inhaled co-administration of olodaterol 5 µg (delivered by the Respimat® Inhaler) and tiotropium (delivered by the Handihaler® as Spiriva Handihaler®), compared to tiotropium (Spiriva Handihaler®) monotherapy on lung function in patients with COPD.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • TiotropiumDrug

    Marketed dose

  • Placebo matching OlodaterolDrug

    One dose

  • OlodaterolDrug

    One dose

  • TiotropiumDrug

    Marketed dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. FEV1 AUC0-3h Response at 12 Weeks; Defined as Change From Baseline to Week 12Time frame: baseline and 12 weeks
  2. Trough FEV1 Response at 12 Weeks; Defined as Change From Baseline to Week 12Time frame: baseline and 12 weeks

Locations

90 sites in 1 country. Site status is shown where the registry gives one.

  • 1222.51.01055 Boehringer Ingelheim Investigational Site

    Florence, Alabama

  • 1222.51.01087 Boehringer Ingelheim Investigational Site

    Jasper, Alabama

  • 1222.51.01066 Boehringer Ingelheim Investigational Site

    Phoenix, Arizona

  • 1222.51.01069 Boehringer Ingelheim Investigational Site

    Scottsdale, Arizona

  • 1222.51.01040 Boehringer Ingelheim Investigational Site

    Anaheim, California

  • 1222.51.01064 Boehringer Ingelheim Investigational Site

    Encinitas, California

  • 1222.51.01060 Boehringer Ingelheim Investigational Site

    Fullerton, California

  • 1222.51.01084 Boehringer Ingelheim Investigational Site

    Lincoln, California

  • 1222.51.01041 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 1222.51.01094 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 1222.51.01015 Boehringer Ingelheim Investigational Site

    Torrance, California

  • 1222.51.01052 Boehringer Ingelheim Investigational Site

    Boulder, Colorado

  • 1222.51.01010 Boehringer Ingelheim Investigational Site

    Wheat Ridge, Colorado

  • 1222.51.01042 Boehringer Ingelheim Investigational Site

    Wheat Ridge, Colorado

  • 1222.51.01070 Boehringer Ingelheim Investigational Site

    Stamford, Connecticut

  • 1222.51.01006 Boehringer Ingelheim Investigational Site

    Clearwater, Florida

  • 1222.51.01021 Boehringer Ingelheim Investigational Site

    Clearwater, Florida

  • 1222.51.01082 Boehringer Ingelheim Investigational Site

    Clearwater, Florida

  • 1222.51.01065 Boehringer Ingelheim Investigational Site

    DeLand, Florida

  • 1222.51.01051 Boehringer Ingelheim Investigational Site

    Jacksonville, Florida

  • 1222.51.01092 Boehringer Ingelheim Investigational Site

    Jacksonville, Florida

  • 1222.51.01081 Boehringer Ingelheim Investigational Site

    Ormond Beach, Florida

  • 1222.51.01054 Boehringer Ingelheim Investigational Site

    Panama City, Florida

  • 1222.51.01062 Boehringer Ingelheim Investigational Site

    Pensacola, Florida

  • 1222.51.01088 Boehringer Ingelheim Investigational Site

    Port Orange, Florida

  • 1222.51.01079 Boehringer Ingelheim Investigational Site

    Tamarac, Florida

  • 1222.51.01075 Boehringer Ingelheim Investigational Site

    Atlanta, Georgia

  • 1222.51.01076 Boehringer Ingelheim Investigational Site

    Austell, Georgia

  • 1222.51.01057 Boehringer Ingelheim Investigational Site

    Duluth, Georgia

  • 1222.51.01086 Boehringer Ingelheim Investigational Site

    Lawrenceville, Georgia

  • 1222.51.01019 Boehringer Ingelheim Investigational Site

    Coeur d'Alene, Idaho

  • 1222.51.01027 Boehringer Ingelheim Investigational Site

    Eagle, Idaho

  • 1222.51.01048 Boehringer Ingelheim Investigational Site

    Arlingron Heights, Illinois

  • 1222.51.01044 Boehringer Ingelheim Investigational Site

    River Forest, Illinois

  • 1222.51.01043 Boehringer Ingelheim Investigational Site

    Skokie, Illinois

  • 1222.51.01090 Boehringer Ingelheim Investigational Site

    Louisville, Kentucky

  • 1222.51.01023 Boehringer Ingelheim Investigational Site

    Lafayette, Louisiana

  • 1222.51.01071 Boehringer Ingelheim Investigational Site

    Opelousas, Louisiana

  • 1222.51.01050 Boehringer Ingelheim Investigational Site

    North Dartmouth, Massachusetts

  • 1222.51.01049 Boehringer Ingelheim Investigational Site

    Ann Arbor, Michigan

Showing 40 of 90 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.